Here's Why Humana (HUM) is a Strong Value Stock

Humana (HUM), a prominent U.S. healthcare plan provider, is identified as a strong value stock, holding a Zacks Rank #2 (Buy) with a VGM Score of B and a Value Style Score of A. This assessment is underpinned by attractive valuation metrics, including a forward P/E ratio of 17.15, a recent upward revision in its fiscal 2025 earnings estimate to $17.05 per share, and a consistent average earnings surprise of +9.6%, positioning it for investor consideration.

Analysis

Humana (HUM), a prominent U.S. healthcare plan provider, currently holds a Zacks Rank #2 (Buy) and a strong Value Style Score of A, complemented by a VGM Score of B. This robust positioning is attributed to attractive valuation metrics, notably a forward P/E ratio of 17.15, which positions it favorably for value-oriented investors.

The company demonstrates solid financial momentum, with one analyst recently revising fiscal 2025 earnings estimates higher, leading to a Zacks Consensus Estimate increase of $0.06 to $17.05 per share. Furthermore, Humana has consistently exceeded expectations, reporting an average earnings surprise of +9.6%.

The combination of a high Zacks Rank and strong Style Scores (A for Value, B for VGM) suggests a high probability of outperformance, aligning with Zacks' methodology that stocks with a #1 or #2 Rank and A or B Style Scores tend to maximize returns. This analytical framework underscores Humana's potential for sustained positive performance.

Key Decisions for Investors

• Investors should consider Humana (HUM) for its strong fundamental profile, including its Zacks Rank #2 (Buy) and attractive Value Style Score of A.
• Monitor future earnings revisions and the company's ability to maintain its average earnings surprise of +9.6% as key performance indicators.
• Evaluate HUM's forward P/E of 17.15 against industry peers to confirm its relative value proposition within the healthcare sector.